Detalle Publicación

ARTÍCULO
Alcoholic-related liver disease: pathogenesis, management and future therapeutic developments
Autores: Argemí Ballbé, José María (Autor de correspondencia); Ventura-Cots, M.; Rachakonda, V.; Bataller, R.
Título de la revista: REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS
ISSN: 1130-0108
Volumen: 112
Número: 11
Páginas: 869 - 878
Fecha de publicación: 2020
Resumen:
Alcohol-related liver disease (ALD) is the most frequent cause of advanced chronic liver disease worldwide. Excessive and prolonged alcohol use leads to ALD, which ranges from early forms such as alcoholic fatty liver (AFL) and alcoholic steatohepatitis (ASH), through progressive fibrosis to cirrhosis and the development of hepatocellular cancer (HCC). In addition, patients with underlying ALD and continuous alcohol use can develop alcoholic hepatitis (AH), which presents a rapid progression of liver failure and has a high short-term mortality. Genetic, environmental and epigenetic factors influence the progression of ALD to more severe forms. The pathogenesis of ALD is complex and involves multiple pathways. Recent translational studies have demonstrated a key role of the gut-liver axis and innate immunity in hepatocellular damage and fibrosis. In severe forms of AH, hepatocellular de-differentiation and systemic inflammation contribute to liver failure and multiorgan failure. Alcohol abstinence is the cornerstone of therapy for ALD and the prevention of its complications, but the efficacy and accessibility of psycho-familial-social interventions is still poor and effective public health policies to limit problematic alcohol use need to be implemented. Prednisolone is the only current option for AH, with a transient beneficial effect over placebo. ...